Sensimed SA

Sensimed SA, a Swiss company, has developed a unique technology platform on non-invasive soft contact lens-based solution. The first application, the SENSIMED Triggerfish®, provides an automated recording of continuous ocular dimensional change over 24 hours with the aim of revolutionizing glaucoma management enhancing personalization of patient care.

The SENSIMED Triggerfish® received the CE mark in 2010 and was approved by the U.S. Food and Drug Administration (FDA) in 2016. Since 2018 the device is registered in Japan at the Pharmaceuticals and Medical Devices Agency (PMDA).

Other non-invasive on-eye sensing applications are in development to provide clinically pertinent data with the same continuous monitoring approach. The Company is furthermore focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The data, analysed and modeled on an ongoing basis, is processed in an attempt to identify pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy of treatment.

The Company is directly positioned at the convergence between devices, treatment and information. Sensimed believes that with this global knowledge-based approach it will be possible to provide valuable insights that allow ophthalmologists to better understand and treat glaucoma.
Sensimed became a subsidiary of SEED CO., Ltd after the acquisition of a majority participation end of 2019.

Company’s Keywords:

healthcare, ophthalmology, mems, medical devices, startup med tech, microtechnology, sensimed triggerfish, glaucoma, smart contact lens, ocular dimensional change, machine learning, contact lens sensor, sensor